Skip to main content
  • Moderna Therapeutics Provides Mid-Year Corporate Update, Announces Continued Clinical Development Progress and Pipeline Acceleration

    Eleven mRNA-based development candidates nominated to date across ventures and partners

    • Two Phase 1 studies underway for mRNA-based infectious disease vaccines
    • CTA filed for Phase 1 study of AZD8601, AstraZeneca’s investigational mRNA-based Therapeutic that encodes for VEGF-A
    • Eight candidates advancing through IND-enabling studies

    Several additional clinical studies planned to initiate in 2016

  • AstraZeneca and Moderna announce filing of first clinical trial application in messenger RNA Therapeutics™ collaboration

    “Developing regenerative therapies for the treatment of cardiometabolic disease is a hugely exciting and innovative area. We believe that using mRNA Therapeutics to initiate a strong, local and transient surge of VEGF-A expression could help us overcome challenges associated with previous approaches to regulate this protein in tissues.”

    Marcus Schindler, Vice President, Innovative Medicines & Early Development at AstraZeneca

  • Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics™ for Cystic Fibrosis

    “Moderna’s messenger RNA Therapeutics represent a promising new approach that could provide functional CFTR proteins to the lungs of people with CF, which would complement our existing approach of using CFTR modulators to treat CF.”

    David Altshuler, M.D., Ph.D., Vertex’s Executive Vice President, Global Research and Chief Scientific Officer

  • Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer

    Collaboration Combines Merck's Leadership in Immuno-Oncology with Moderna's Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities

  • Moderna is a Science magazine Top Employer.

Our Mission

Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.